In the UK, the reporting of suspected side effects and drug interactions is a vital component of ongoing drug safety monitoring
The article breaks down what microdosing really means, why these tiny doses are not FDA approved, and the evidence gaps clinicians are raising
Regular sauna sessions combined with periodic Glutathione IV therapy can help maintain detoxification and overall wellness
Chiarugi, A., Dlle, C., Felici, R
BPC-157 can induce nitric oxide generation and activate eNOS (endothelial nitric oxide synthase), which is associated with tissue repair
In the News Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis Understanding the types of leukemia Reflections on caring for cancer patients during the COVID-19 pandemic New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients ARCHIVED: Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies Present Title & Affiliation Primary Appointment Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX Dual/Joint/Adjunct Appointment Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX Research Interests Patients with AML and BPDCN: CD123-targeted clinical trial with SL-401
